Amneal Pharmaceuticals (AMRX) Tops Q1 EPS by 11c, Offers FY Guidance

Amneal Pharmaceuticals (: AMRX) reported Q1 EPS of $0.20, $0.11 better than the analyst estimate of $0.09. Revenue for the quarter came in at $499 million versus the consensus estimate of $444.23 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2020 EPS of $0.45-$0.60, versus the consensus of $0.49. Amneal Pharmaceuticals sees FY2020 revenue of $1.875-1.975 billion, versus the consensus of $1.87 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Cloudastructure restructures preferred stock, issues $1.3M promissory note
• Vertex to acquire Crinetics Pharmaceuticals for $10 billion